白蛋白结合型紫杉醇联合阿帕替尼辅助中药治疗晚期子宫内膜癌疗效观察  

Clinical effect of albumin binding paclitaxel combined with apatinib in the auxiliary Chinese medicine treatment of advanced endometrial cancer

作　　者：齐曼[1] 芦秋彤 刘少卿[1] 张娟 崔艳萍 QI Man;LU Qiutong;LIU Shaoqing;ZHANG Juan;CUI Yanping(Chemotherapy Centre,Chengde Central Hospital,Hebei Chengde 067000,China;Department of Pharmacy,Chengde Central Hospital,Hebei Chengde 067000,China;Xinle City Hospital,Hebei Shijiazhuang 050700,China)

机构地区：[1]承德市中心医院放化疗中心,河北承德067000 [2]承德市中心医院药剂科临床药学室,河北承德067000 [3]新乐市医院,河北石家庄050700

出　　处：《现代肿瘤医学》2021年第23期4176-4180,共5页Journal of Modern Oncology

基　　金：河北省承德市科技支撑项目(编号:201904A013)。

摘　　要：目的:探讨白蛋白结合型紫杉醇联合阿帕替尼辅助中药治疗晚期子宫内膜癌的临床疗效及对血清CYFRA 21-1水平的影响。方法:将本院2018年10月至2019年10月收治的85例晚期子宫内膜癌患者按照随机数字表法分为两组,对照组(43例):白蛋白结合型紫杉醇+卡铂治疗3个月,同时口服消癌平片;观察组(42例)在对照组基础上增加阿帕替尼。治疗结束后,实体瘤疗效评价标准RECIST 6.0评估临床疗效,记录治疗后不良反应情况,测定血清CYFRA 21-1水平及KPS评分。结果:治疗后观察组的疾病控制率、总体有效率(92.8%、61.9%)高于对照组(72.1%、37.2%)(P<0.05)。观察组总不良反应发生率(35.70%)与对照组(25.58%)比较差异无统计学意义(P>0.05)。对照组、观察组治疗1个月、3个月后血清CYFRA 21-1水平低于治疗前,而1个月、3个月KPS评分高于治疗前(P<0.05);观察组治疗1个月、3个月后血清CYFRA 21-1水平低于对照组,治疗1个月、3个月后KPS评分高于对照组(P<0.05)。结论:白蛋白结合型紫杉醇联合阿帕替尼辅助中药治疗可提高子宫内膜癌总有效率,降低血清CYFRA 21-1水平,对晚期子宫内膜癌的临床治疗疗效明显。Objective:To investigate the clinical effect of albumin binding paclitaxel combined with apatinib in the auxiliary Chinese medicine treatment of advanced endometrial cancer and its effect on serum CYFRA 21-1.Methods:85 patients with advanced endometrial cancer in our hospital from October 2018 to October 2019 were randomly divided into two groups,control group with 43 cases given with albumin combined paclitaxel+carboplatin for 3 months,and orally Xiao Aiping tablets,and observation group with 42 cases treated with apatinib on the basis of the control group.At the end of the treatment,RECIST 6.0 was used to evaluate the clinical effect.The adverse reactions,the level of CYFRA 21-1 and KPS were compared between two groups.Results:After treatment,the disease control rate and the overall effective rate of the observation group(92.8%,61.9%)were higher than those of the control group(72.1%,37.2%)(P<0.05).There was no significant difference in the total adverse reaction rate between the observation group(35.70%)and the control group(25.58%)(P>0.05).The level of serum CYFRA 21-1 at the 1st month and 3rd month after treatment in the control group and the observation group were lower than that before treatment,while the KPS score in the observation group was higher than that before treatment(P<0.05).The level of serum CYFRA 21-1 at the 1st month and 3rd month after treatment in the observation group were lower than that in the control group,and the KPS score in the observation group was higher than that in the control group(P<0.05).Conclusion:Albumin binding paclitaxel combined with apatinib in the auxiliary Chinese medicine treatment of advanced endometrial cancer can improve the overall efficiency of endometrial cancer,reduce serum CYFRA 21-1 level,and has a significant clinical effect on advanced endometrial cancer.

关 键 词：白蛋白结合型紫杉醇 阿帕替尼 晚期子宫内膜癌 临床疗效 CYFRA 21-1 

分 类 号：R737.33[医药卫生—肿瘤]